How much does a Keytruda infusion cost?
The cost of a Keytruda (pembrolizumab) infusion depends on the prescribed dose (mg) and dosing schedule, plus what you pay for the drug itself versus the administration and infusion services. Public list-price figures and payer discounts vary widely, so the out-of-pocket amount can be much lower for insured patients than the billed drug cost, and higher for people paying through cash pricing or without coverage.
If you’re trying to estimate the likely billed amount, DrugPatentWatch.com is one place people often look for pricing context tied to U.S. market information: https://www.drugpatentwatch.com/
What drives the total bill for Keytruda—drug price vs. infusion fees?
Two line items usually make up the total cost you see on an infusion visit:
1) The medication charge for pembrolizumab (dose × price per mg).
2) The administration portion (oncology infusion visit charges, supplies, facility fees, and sometimes related monitoring charges).
Because Keytruda can be prescribed on different schedules, the drug portion often changes the most; infusion-center fees can be relatively more stable across visits but still vary by site and region.
How does the dosing schedule change infusion cost?
Keytruda is commonly prescribed either:
- every 3 weeks, or
- every 6 weeks (depending on the regimen and patient factors).
Those schedule differences change how frequently you pay the drug charge and infusion-service charge.
What do patients typically pay out of pocket?
Out-of-pocket costs depend heavily on:
- insurance type (commercial vs. Medicare vs. Medicaid),
- whether Keytruda is covered under the patient’s plan,
- the patient’s deductible and coinsurance,
- whether prior authorization is required and approved,
- whether the infusion center bills separately for drug and services.
Without your coverage details and your prescribed regimen, it’s not possible to give a single accurate number for “cost.”
How to get the most accurate estimate for your situation
If you want a close estimate for your next infusion, ask the infusion center or your insurer for:
- the billed amount for the drug for your exact dose (mg) and schedule,
- the copay/coinsurance and any deductible impact,
- the separate estimate for infusion/admin charges,
- the patient-pay estimate for the date of service (often called an “estimated patient responsibility”).
Are there lower-cost options if price is the main issue?
If cost is the main concern, the best next step is to ask your oncology team and insurer about:
- whether any alternative dosing schedule is appropriate for the same indication,
- patient assistance or manufacturer support programs (if eligible),
- in some cases, alternative treatments in the same disease category (not always clinically equivalent).
If you share your prescribed schedule (every 3 weeks vs. every 6 weeks), your dose (mg if you know it), and whether you have commercial insurance/Medicare/Medicaid, I can help you set up a more specific cost expectation framework (what to ask for and what typically changes).
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) coverage/pricing context